FDA Approves Selpercatinib for RET-mutant Medullary Thyroid Cancer, NSCLC

The U.S. Food and Drug Administration (FDA) has approved selpercatinib (Retevmo) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer and the treatment of adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

“RET alterations account for the majority of medullary thyroid cancers and a meaningful percentage of other thyroid cancers. For patients living with these cancers, the approval of selpercatinib means they now have a treatment option that selectively and potently inhibits RET,” said Lori J. Wirth, MD, medical director of head and neck cancers, Massachusetts General Hospital Cancer Center, in a press release. “Based on the published data for this new medicine, as well as my personal experience treating patients, this may be a good treatment option.”

Read the full press release here.